144 related articles for article (PubMed ID: 38330545)
1. The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial.
Lorenzon R; Ribet C; Pitoiset F; Aractingi S; Banneville B; Beaugerie L; Berenbaum F; Cacoub P; Champey J; Chazouilleres O; Corpechot C; Fautrel B; Mekinian A; Regnier E; Saadoun D; Salem JE; Sellam J; Seksik P; Vicaut E; Rosenzwajg M; Klatzmann D
J Autoimmun; 2024 Apr; 144():103172. PubMed ID: 38330545
[TBL] [Abstract][Full Text] [Related]
2. Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study.
Barde F; Lorenzon R; Vicaut E; Rivière S; Cacoub P; Cacciatore C; Rosenzwajg M; Daguenel-Nguyen A; Fain O; Klatzmann D; Mekinian A
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38580347
[TBL] [Abstract][Full Text] [Related]
3. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.
Rosenzwajg M; Lorenzon R; Cacoub P; Pham HP; Pitoiset F; El Soufi K; RIbet C; Bernard C; Aractingi S; Banneville B; Beaugerie L; Berenbaum F; Champey J; Chazouilleres O; Corpechot C; Fautrel B; Mekinian A; Regnier E; Saadoun D; Salem JE; Sellam J; Seksik P; Daguenel-Nguyen A; Doppler V; Mariau J; Vicaut E; Klatzmann D
Ann Rheum Dis; 2019 Feb; 78(2):209-217. PubMed ID: 30472651
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
5. [Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome].
Bernard F; Romano A; Granel B
Rev Med Interne; 2010 Feb; 31(2):116-27. PubMed ID: 19962219
[TBL] [Abstract][Full Text] [Related]
6. How GRAIL controls Treg function to maintain self-tolerance.
Fathman CG; Yip L; Gómez-Martín D; Yu M; Seroogy CM; Hurt CR; Lin JT; Jenks JA; Nadeau KC; Soares L
Front Immunol; 2022; 13():1046631. PubMed ID: 36569931
[TBL] [Abstract][Full Text] [Related]
7. Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation.
Tchitchek N; Nguekap Tchoumba O; Pires G; Dandou S; Campagne J; Churlaud G; Fourcade G; Hoffmann TW; Strozzi F; Gaal C; Bonny C; Le Chatelier E; Erlich SD; Sokol H; Klatzmann D
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35917175
[TBL] [Abstract][Full Text] [Related]
8. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
9. Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp
Ferreira RC; Castro Dopico X; Oliveira JJ; Rainbow DB; Yang JH; Trzupek D; Todd SA; McNeill M; Steri M; Orrù V; Fiorillo E; Crouch DJM; Pekalski ML; Cucca F; Tree TI; Vyse TJ; Wicker LS; Todd JA
Front Immunol; 2019; 10():2606. PubMed ID: 31781109
[TBL] [Abstract][Full Text] [Related]
10. Splicing factor SRSF1 controls distinct molecular programs in regulatory and effector T cells implicated in systemic autoimmune disease.
Cassidy MF; Herbert ZT; Moulton VR
Mol Immunol; 2022 Jan; 141():94-103. PubMed ID: 34839165
[TBL] [Abstract][Full Text] [Related]
11. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
Humrich JY; Cacoub P; Rosenzwajg M; Pitoiset F; Pham HP; Guidoux J; Leroux D; Vazquez T; Riemekasten G; Smolen JS; Tsokos G; Klatzmann D
Ann Rheum Dis; 2022 Dec; 81(12):1685-1694. PubMed ID: 35973803
[TBL] [Abstract][Full Text] [Related]
12. Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren's syndrome.
Keindl M; Davies R; Bergum B; Brun JG; Hammenfors D; Jonsson R; Lyssenko V; Appel S
Arthritis Res Ther; 2022 May; 24(1):101. PubMed ID: 35526080
[TBL] [Abstract][Full Text] [Related]
13. Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.
Tahvildari M; Dana R
J Immunol; 2019 Dec; 203(11):2749-2755. PubMed ID: 31740549
[TBL] [Abstract][Full Text] [Related]
14. Relationship of chronic rhinosinusitis with Sjogren's syndrome, systemic lupus erythematosus, and ankylosing spondylitis.
Lee IH; Kim DK
Rhinology; 2023 Apr; 61(2):124-131. PubMed ID: 36480330
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T cells and immunoglobulin E: A new therapeutic link for autoimmunity?
Palomares O; Elewaut D; Irving PM; Jaumont X; Tassinari P
Allergy; 2022 Nov; 77(11):3293-3308. PubMed ID: 35852798
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-13: A promising therapeutic target for autoimmune disease.
Mao YM; Zhao CN; Leng J; Leng RX; Ye DQ; Zheng SG; Pan HF
Cytokine Growth Factor Rev; 2019 Feb; 45():9-23. PubMed ID: 30581068
[TBL] [Abstract][Full Text] [Related]
17. Acute Neurologic Manifestations of Systemic Immune-Mediated Diseases.
Galetta K; Bhattacharyya S
Semin Neurol; 2021 Oct; 41(5):541-553. PubMed ID: 34619780
[TBL] [Abstract][Full Text] [Related]
18. The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.
Seelig E; Howlett J; Porter L; Truman L; Heywood J; Kennet J; Arbon EL; Anselmiova K; Walker NM; Atkar R; Pekalski ML; Rytina E; Evans M; Wicker LS; Todd JA; Mander AP; Bond S; Waldron-Lynch F
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282826
[TBL] [Abstract][Full Text] [Related]
19. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.
Mizui M; Tsokos GC
Front Immunol; 2018; 9():786. PubMed ID: 29755456
[TBL] [Abstract][Full Text] [Related]
20. [Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome].
Ampélas JF; Wattiaux MJ; Van Amerongen AP
Encephale; 2001; 27(6):588-99. PubMed ID: 11865567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
